EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Outcomes of Kidney Transplantation in Scleroderma Patients: A U.S. National Database Study

Shengliang He, Farah Yasmin, Francis Wilson, Sarat Kuppachi, Abhishek Kumar

Clinical Kidney Journal · 11.11.2026

DOI: 10.1093/ckj/sfag400 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Kidney Journal, online erschienen am 11.11.2026. Verfasst von Shengliang He und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Scleroderma is a systemic autoimmune disease that can progress to end-stage renal disease. Historically, kidney transplantation in scleroderma patients was associated with poor outcomes, but contemporary results in the United States remain understudied.

Methods

Adult kidney transplant recipients with scleroderma (1990-2020) were identified from the SRTR database. Control groups included patients with diabetes mellitus, IgA nephropathy, and all non-scleroderma recipients. Kaplan-Meier methods were used to estimate patient survival and graft survival.

Results

Among 347,598 kidney transplant recipients, 399 had scleroderma. Compared with non-scleroderma recipients, those with scleroderma were more likely to receive a living donor transplant (45.1% vs. 34.3%, p<0.001), be female (77.9% vs. 39.3%, p<0.001), be white (86.5% vs. 66.8%, p<0.001), and have a lower body mass index (22.9 vs. 27.1 kg/m², p<0.001). After adjustment for various factors, scleroderma was associated with higher mortality compared with non-scleroderma recipients (HR 1.39, 95% CI 1.19–1.65) and recipients with IgA nephropathy (HR 2.98, 95% CI 2.48–3.58), but comparable to recipients with diabetes mellitus (HR 0.88, 95% CI 0.75–1.04). Death-censored graft survival was comparable between recipients with scleroderma and those with diabetes mellitus (HR 0.91, 95% CI 0.69–1.19) or non-scleroderma recipients (HR 1.27, 95% CI 0.97–1.67), but was inferior compared with recipients with IgA nephropathy (HR 2.11, 95% CI 1.59–2.80).

Conclusion

Outcomes of kidney transplantation in scleroderma patients are similar to patients with diabetes but inferior to patients with IgA nephropathy and kidney transplant is a viable option for scleroderma patients with end stage kidney disease.

Zitieren

APA

He, S., Yasmin, F., Wilson, F., Kuppachi, S., & Kumar, A. (2026). Outcomes of Kidney Transplantation in Scleroderma Patients: A U.S. National Database Study. Clinical Kidney Journal. https://doi.org/10.1093/ckj/sfag400

Vancouver

He S, Yasmin F, Wilson F, Kuppachi S, Kumar A. Outcomes of Kidney Transplantation in Scleroderma Patients: A U.S. National Database Study. Clinical Kidney Journal. 2026. doi:10.1093/ckj/sfag400

BibTeX
@article{He2026,
  author = {He, Shengliang and Yasmin, Farah and Wilson, Francis and Kuppachi, Sarat and Kumar, Abhishek},
  title = {Outcomes of Kidney Transplantation in Scleroderma Patients: A U.S. National Database Study},
  journal = {Clinical Kidney Journal},
  year = {2026},
  doi = {10.1093/ckj/sfag400}
}
Kostenlos starten →